<DOC>
	<DOCNO>NCT02799472</DOCNO>
	<brief_summary>This study design explore activity granulocyte-macrophage colony stimulate factor ( GM-CSF ) signal pathway subject rheumatoid arthritis ( RA ) , potential impact inhibition axis GSK3196165 , evaluate whether difference GM-CSF axis subject early RA compare establish disease . This study also aim establish potential impact GSK3196165 inflammatory structural joint damage hand/wrist use magnetic resonance imaging ( MRI ) . This randomized Phase IIa , multi-center , double-blind , placebo-controlled parallel group study . Approximately 40 subject active RA despite treatment disease-modifying antirheumatic drug ( DMARDs ) ( include conventional biologic ) randomize study , follow screen period 6 week . The total treatment period 10 week , 12-week follow-up period last dose ( Week 22 ) .</brief_summary>
	<brief_title>Mechanistic Study GSK3196165 Plus Methotrexate ( MTX ) Subjects With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Age &gt; =18 year time signing informed consent . Meets American College Rheumatology ( ACR ) /European League Against Rheumatism ( EULAR ) 2010 RA Classification Criteria AND subject diagnose age 16 year . Functional class I , II III define 1992 ACR Classification Functional Status RA . Active disease define : Swollen joint count &gt; =4 ( 66joint count ) tender joint count &gt; =4 ( 68joint count ) screen Day 1 . AND • Disease activity score 28 different joint Creactive protein ( CRP ) value ( DAS28 [ CRP ] ) &gt; =3.2 screening . AND • CRP &gt; =3.0 milligram ( mg ) /liter ( L ) . Signs inflammation synovitis MRI scan mostaffected hand . Must currently take MTX ( 1525 mg weekly ) ( oral/injected ) least 12 week screening , change route administration , stable tolerate dose &gt; =4 week prior Day 1 . A stable dose MTX &gt; =7.5 mg/week acceptable , MTX dose reduce reason document intolerance MTX , example ( e.g . ) hepatic hematologic toxicity , per local requirement . Body weight &gt; =45 kilogram ( kg ) . Male female subject eligible participate long meet agree abide contraceptive criterion . Capable give sign informed consent describe protocol include compliance requirement restriction list consent form protocol . Willing continue initiate treatment oral folic acid ( least 5 mg/week ) equivalent treat entire study ( mandatory comedication MTX treatment ) . Diffusing capacity lung carbon monoxide ( DLCO ) &gt; =60 % predict ; force expiratory volume 1 second ( FEV1 ) &gt; =70 % predict . No evidence active latent infection Mycobacterium tuberculosis ( TB ) . Pregnant lactating , woman plan become pregnant initiate breastfeeding . History inflammatory rheumatologic autoimmune disorder , Sjögren 's syndrome secondary RA . History respiratory disease ( opinion investigator ) would compromise subject safety ability subject complete study ( e.g . significant interstitial lung disease , pulmonary fibrosis , chronic obstructive pulmonary disease ( COPD ) , moderatesevere asthma , bronchiectasis , previous pulmonary alveolar proteinosis [ PAP ] ) . Clinicallysignificant ( opinion investigator ) persistent cough clinically significant unstable dyspnea unexplained . Significant unstable uncontrolled acute chronic disease , opinion investigator , could confound result study put subject undue risk . A history malignancy . Contraindication MRI scan . Current/previous Hepatitis B virus ( HBV ) , Hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ) 1 2 infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>GSK3196165</keyword>
	<keyword>magnetic resonance imaging ( MRI )</keyword>
	<keyword>disease-modifying antirheumatic drug ( DMARDs )</keyword>
	<keyword>granulocyte-macrophage colony stimulate factor ( GM-CSF )</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Methotrexate</keyword>
</DOC>